Association of Dyslipidemia with Chronic Kidney Disease  in Patients Requiring Renal Replacement Therapy

Muhammad Ansar; Malik Nadeem Azam Khan; Asif Faoorq; Hafiz Asad Saeed; Falak Naz Alvi; Haider Rana

doi:10.51253/pafmj.v75i5.10845

Authors

Muhammad Ansar Department of Medicine, Combined Military Hospital, Kharian/National University of Medical Sciences (NUMS) Pakistan
Malik Nadeem Azam Khan Department of Medicine, Combined Military Hospital, Kharian/National University of Medical Sciences (NUMS) Pakistan
Asif Faoorq Department of Medicine, Combined Military Hospital, Kharian/National University of Medical Sciences (NUMS) Pakistan
Hafiz Asad Saeed Department of Medicine, Combined Military Hospital, Nowshera /National University of Medical Sciences (NUMS) Pakistan
Falak Naz Alvi Department of Medicine, Combined Military Hospital, Kharian/National University of Medical Sciences (NUMS) Pakistan
Haider Rana Department of Medicine, Combined Military Hospital, Kharian/National University of Medical Sciences (NUMS) Pakistan

DOI:

https://doi.org/10.51253/pafmj.v75i5.10845

Keywords:

Chronic Kidney Disease, Cholesterol, Dyslipidemia, Hemodialysis, Renal Replacement therapy

Abstract

Objective: To highlight the association of dyslipidemia in patients of Chronic Kidney Disease requiring Hemodialysis (CKD-5D) at a tertiary care hospital.

Study Design: Comparative cross-sectional study

Place and Study of Duration: Department of Nephrology, Combined Military Hospital, Kharian, Pakistan, Jan to Jun 2023.

Methodology: Using consecutive sampling, CKD patients of either gender with age > 20 years, both dialysis dependent (CKD-5D) and non-dialysis (CKD-5ND) were included and divided into two Groups of 50 patients each. Serum cholesterol, triglycerides (TGs), low-density lipoprotein (LDL), and high-density lipoprotein (HDL) levels in both Group patients were assessed and analyzed. Measures of association like odds ratio and prevalence ratio were calculated.

Results: Diabetes Mellitus was the most common cause of CKD in both groups. Majority of Group A patients 20(40.0%) had CKD-5 for 3-5 years as compared to majority of Group B patients 22(44.0%) who had CKD-5 for > 5 years with dialysis dependency for at-least 1 year (p=0.805). LDL-C levels comparison in both groups showed hyper-LDL-cholesterolemia in 30(60.0%) vs 37(74.0%) of Group A (CKD-5ND) and Group B (CKD-5D) patients, respectively (p=0.109). Odds ratio (OR) and prevalence ratio (PR) were > 1 indicating there were higher odds and higher prevalence of raised LDL levels in CKD-5D (OR=1.89 [95% CI 0.812 - 4.431], p=0.069, PR = 1.23).

Conclusion: There is high prevalence of dyslipidemia in advancing CKD patients and with declining eGFR dyslipidemia risk increases leading to increased incidence of fatal events.

Downloads

Download data is not yet available.

References

1. Lv JC, Zhang LX. Prevalence and Disease Burden of Chronic Kidney Disease. In: Liu BC, Lan HY, Lv LL, editors. Renal Fibrosis: Mechanisms and Therapies; 2019. p. 3–15. (Advances in Experimental Medicine and Biology; vol. 1165).

https://doi.org/10.1007/978-981-13-8871-2_1

2. Shrestha N, Gautam S, Mishra SR, Virani SS, Dhungana RR. Burden of chronic kidney disease in the general population and high-risk Groups in South Asia: A systematic review and meta-analysis. PLoS One 2021; 16(10): e0258494.

https://doi.org/10.1371/journal.pone.0258494

3. Pappan N, Rehman A. Dyslipidemia. In: StatPearls: StatPearls Publishing; 2023. Available from:

https://www.ncbi.nlm.nih.gov/books/NBK560891/

4. Hager MR, Narla AD, Tannock LR. Dyslipidemia in patients with chronic kidney disease. Rev Endocr Metab Disord 2017; 18(1): 29–40. https://doi.org/10.1007/s11154-016-9402-z

5. Kopin L, Lowenstein CJ. Dyslipidemia. Ann Intern Med 2017; 167(11): ITC81–96.

https://doi.org/10.7326/AITC201712050

6. Rosenstein K, Tannock LR. Dyslipidemia in Chronic Kidney Disease. In: Feingold KR, Anawalt B, Blackman MR, et al., editors. Endotext: MDText.com, Inc.; 2000. Available from: https://www.ncbi.nlm.nih.gov/books/NBK305899/

7. Reule S, Ishani A, Goldsmith D. Dyslipidemia and Chronic Kidney Disease. In: Chronic Renal Disease. 2nd ed. Elsevier; 2020. p. 1093–101.

https://doi.org/10.1016/B978-0-12-815876-0.00066-8

8. Pontremoli R, Bellizzi V, Bianchi S, Bigazzi R, Cernaro V, Del Vecchio L, et al. Management of dyslipidaemia in patients with chronic kidney disease: a position paper endorsed by the Italian Society of Nephrology. J Nephrol 2020; 33(3): 417–430.

https://doi.org/10.1007/s40620-020-00736-x

9. Kochan Z, Szupryczynska N, Malgorzewicz S, Karbowska J. Dietary Lipids and Dyslipidemia in Chronic Kidney Disease. Nutrients 2021; 13(9): 3138.

https://doi.org/10.3390/nu13093138

10. Theofilis P, Vordoni A, Koukoulaki M, Vlachopanos G, Kalaitzidis RG. Dyslipidemia in Chronic Kidney Disease: Contemporary Concepts and Future Therapeutic Perspectives. Am J Nephrol 2021; 52(9): 693–701.

https://doi.org/10.1159/000518650

11. Jankowski J, Floege J, Fliser D, Böhm M, Marx N. Cardiovascular Disease in Chronic Kidney Disease: Pathophysiological Insights and Therapeutic Options. Circulation 2021; 143(11): 1157–1172. https://doi.org/10.1161/CIRCULATIONAHA.120.050686

12. Ferro CJ, Mark PB, Kanbay M, Sarafidis P, Heine GH, Rossignol P, et al. Lipid management in patients with chronic kidney disease. Nat Rev Nephrol 2018; 14(12): 727–749.

https://doi.org/10.1038/s41581-018-0072-9

13. Mikolasevic I, Žutelija M, Mavrinac V, Orlic L. Dyslipidemia in patients with chronic kidney disease: etiology and management. Int J Nephrol Renovasc Dis 2017; 10: 35–45.

https://doi.org/10.2147/IJNRD.S101808

14. Tunbridge MJ, Jardine AG. Atherosclerotic Vascular Disease Associated with Chronic Kidney Disease. Cardiol Clin 2021; 39(3): 403–414. https://doi.org/10.1016/j.ccl.2021.04.009

15. Dušejovská M, Vecka M, Rychlík I, Žák A. Dyslipidemia in patients with chronic kidney disease: etiology and management. Vnitr Lek 2020; 66(5): 275–281.

16. Kosugi T, Eriguchi M, Yoshida H, Tasaki H, Fukata F, Nishimoto M, et al. Association between chronic kidney disease and new-onset dyslipidemia: The Japan Specific Health Checkups (J-SHC) study. Atherosclerosis 2021; 332: 24–32. https://doi.org/10.1016/j.atherosclerosis.2021.07.008

17. Carmena R, Ascaso JF, Redon J. Chronic kidney disease as a cardiovascular risk factor. J Hypertens 2020; 38(11): 2110–2121. https://doi.org/10.1097/HJH.0000000000002553

18. Nakano T, Tanaka S, Tsuruya K, Kitazono T. Relationship between serum lipid concentrations and impaired renal function in patients with chronic kidney disease: the Fukuoka Kidney Disease Registry Study. Clin Exp Nephrol 2021; 25(4): 385–393. https://doi.org/10.1007/s10157-020-01996-4

19. Chang TI, Streja E, Ko GJ, Naderi N, Rhee CM, Kovesdy CP, et al. Inverse Association Between Serum Non–High‐Density Lipoprotein Cholesterol Levels and Mortality in Patients Undergoing Incident Hemodialysis. J Am Heart Assoc 2018; 7(12): e009096. https://doi.org/10.1161/JAHA.118.009096